A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma

Oncologist

Volumn 19, Issue 4, 2014, Pages 354-355

  Plimack, Elizabeth R ^a   Tan, Tingting ^a   Wong, Yu Ning ^a   von Mehren, Margaret M ^a   Malizzia, Lois ^a   Roethke, Susan K ^a   Litwin, Samuel ^a   Li, Tianyu ^a   Hudes, Gary R ^a   Haas, Naomi B ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN KINASE C; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; BRYOSTATIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; HUMAN; KIDNEY METASTASIS; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DRUG ADMINISTRATION; KIDNEY NEOPLASMS; MORTALITY; SARCOMA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRYOSTATINS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; HUMANS; KIDNEY NEOPLASMS; MULTIPROTEIN COMPLEXES; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SARCOMA; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84898446585     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0020     Document Type: Article

References (0)